To overcome clients' concerns about losing control and oversight when outsourcing and offshoring research, Chinese CRO WuXi AppTec has bought software that gives clients remote access to study data.
Life Technologies and Merck Serono plan to work together on companion diagnostics, beginning with a buddy diagnostic for a cancer drug.
The Palo Alto, CA-based company scored $30.6 million in a Series B round of financing from a deep-pocketed crowd that includes Citi Ventures, GE Ventures as well as returning backers Khosla Ventures and Floodgate.
The National Cancer Institute (NCI) has taken steps to tie together drug effects and genetic variants in cancers in an enormous database, as research of targeted attacks on tumors have yielded a dizzying amount of info on the vast genetic diversity within malignancies and the compounds that block drivers of disease.
Pinterest has attracted some early activity from pharma companies with a fast-growing platform for sharing visual content. Sounds innocuous enough, yet media consultant Peter Houston writes about some of the potential risks of using the site.
Europeans want to tackle one of the boogeymen of social media in pharma--adverse drug event reporting. In the name of patient safety, regulators and pharma outfits are seeking proposals for how to tap social media and mobile tech to improve detection of adverse reactions to medicines.
Amid digitization of clinical trials, the vaunted venture firm Sequoia Capital has stepped up to lead an $8.4 million Series A round for Comprehend Systems. The deal elevates the profile of Palo Alto, CA-based Comprehend, an upstart provider of web-based analytics software for clinical trials data.
The Budapest-based chemical informatics outfit has inked a 5-year extension to its collaboration with Schrödinger. The deal enables Schrödlinger to integrate ChemAxon's chemistry tools into its enterprise informatics platform, Seurat, and follows a string of other tie-ups with major industry players.
Boehringer Ingelheim has become one of the latest large drugmakers to deepen its commitment to mining massive datasets in its R&D operations. In a plug for the software group's Big Data technology, NextBio touted that Boehringer had renewed its agreement to use its research platform in an expanded capacity.
It's no secret that poor adherence to medication instructions costs healthcare systems billions of dollars a year, and pharma companies have kicked the tires on technologies to alert patients that it's time to take their meds.
Predixion Software has rounded up new investors and a partnership with Accenture ($ACN) to advance analytics in healthcare, life sciences and beyond.
Biopharma outfits have investigated the use of popular social media sites for spreading a variety of messages and gathering plenty of intelligence.
AstraZeneca has again turned to a software startup to aid its drug research. Cambridge, U.K.-based Optibrium scored a licensing deal form the British drug giant, which has decided to adopt the small company's StarDrop software for hunting down pharma compounds for development.
University of Wisconsin researchers have undertaken a genomic study involving patients with cystic fibrosis, aiming to uncover data that explain variation in symptoms among those afflicted with the genetic lung disease. And researchers believe that bioinformatics and other new resources give them an "edge" in the fight to improve treatments, according to the university's release.
Major tech and services firms would love for pharma to give cloud computing a wholehearted embrace, but the reality is that cloud software and services have trickled into the spending plans of drugmakers as they slowly warm up to web-based systems.
With the FDA coming down hard on failings at pharma production plants, Roche has adopted software to improve oversight of its contract manufacturers.
When ex-Google ($GOOG) guys Nat Turner and Zach Weinberg discussed their oncology-focused startup Flatiron Health in August they were big on ambition but low on details.
Deloitte has given the first indication of how it will tap into the decades of electronic health records (EHRs) at its new partner Intermountain Healthcare.
Johnson & Johnson ($JNJ) put bioinformatics at the heart of its inflammatory bowel disease (IBD) plans last week when it hooked its latest innovation center up with Mount Sinai.
Across the pharmaceutical industry inherent and understandable conservatism and secrecy act as a check against the adoption of new technologies and more open ways of working.